Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.

abstract：:'Insignificant' prostate cancer is defined as disease of virulence insufficient to threaten survival. In this review, which describes nine articles and two abstracts discussing almost 800 cases, we discuss the correlation of such 'insignificant' biopsy findings in the context of subsequent radical prostatectomy data. ...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Rossi PJ,Jani AB,Master V

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Gonadotrophin releasing hormone (GnRH) agonists and antagonists reduce testosterone levels for the treatment of advanced and metastatic prostate cancer. Androgen deprivation therapy (ADT) is associated with increased risk of cardiovascular (CV) events and CV disease (CVD), especially in patients with preexis...

journal_title：Prostate cancer and prostatic diseases

authors： Margel D,Ber Y,Peer A,Shavit-Grievink L,Pinthus JH,Witberg G,Baniel J,Kedar D,Rosenbaum E

更新日期：2020-07-31 00:00:00

abstract：BACKGROUND:Prostate cancer is the most common cancer in American men that ranges from low risk states amenable to active surveillance to high-risk states that can be lethal especially if untreated. There is a critical need to develop relatively non-invasive and clinically useful methods for screening, detection, progno...

journal_title：Prostate cancer and prostatic diseases

authors： Eskra JN,Rabizadeh D,Pavlovich CP,Catalona WJ,Luo J

更新日期：2019-09-01 00:00:00

abstract：:As earlier detection of prostate cancer increases because of prostate-specific antigen (PSA) testing, appropriate use for watchful waiting warrants re-evaluation. We have drawn together the significant watchful waiting literature and used it to evaluate the use of watchful waiting in the PSA era. We conducted literatu...

journal_title：Prostate cancer and prostatic diseases

authors： Chodak GW,Warren KS

更新日期：2006-01-01 00:00:00

abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

journal_title：Prostate cancer and prostatic diseases

authors： Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

更新日期：2018-11-01 00:00:00

abstract：:Worldwide disparities exist between geographic regions with regard to prostate cancer incidence and mortality. Countries in East Asia have lower rates of prostate cancer compared with Western countries such as Canada and the US. Some suggest that dietary differences between the two geographic regions, particularly the...

journal_title：Prostate cancer and prostatic diseases

authors： Goetzl MA,Van Veldhuizen PJ,Thrasher JB

更新日期：2007-01-01 00:00:00

abstract：:We hypothesized that factors beyond pathological stage, grade, PSA and margin status would be important predictors of biochemical recurrence (BCR) after radical prostatectomy (RP). A cohort of 3194 patients who underwent RP between 1988 and 2007 and who had neither neoadjuvant therapy nor postoperative adjuvant hormon...

journal_title：Prostate cancer and prostatic diseases

authors： Schroeck FR,Sun L,Freedland SJ,Jayachandran J,Robertson CN,Moul JW

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVES:Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization...

journal_title：Prostate cancer and prostatic diseases

authors： Sargos P,Ferretti L,Gross-Goupil M,Orre M,Cornelis F,Henriques de Figueiredo B,Houédé N,Merino C,Roubaud G,Dallaudiére B,Richaud P,Fléchon A

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...

journal_title：Prostate cancer and prostatic diseases

authors： Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

更新日期：2015-03-01 00:00:00

abstract：:Prostate cancer has been known to run in families for about 40 years and epidemiological studies have demonstrated an increased risk to close relatives of cases. This risk rises markedly when the closeness and number of cases in a cluster increases. There has been considerable debate about the genetic model, in partic...

journal_title：Prostate cancer and prostatic diseases

authors： Eeles RA

更新日期：1999-01-01 00:00:00

abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Assikis V,Goodman M,Ward KC,Riffenburgh RH,Master V

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Approximately 29-38% of all positive surgical margins (PSMs) at radical prostatectomy (RP) involve the apex. The prognostic significance of apical PSM remains unclear. We therefore compared the long-term oncologic outcomes of men with apical PSMs to those with negative PSMs, apical and other PSMs, and other ...

journal_title：Prostate cancer and prostatic diseases

authors： Wadhwa H,Terris MK,Aronson WJ,Kane CJ,Amling CL,Cooperberg MR,Freedland SJ,Abern MR

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Tumour 18F-FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. METHODS:Retrospective analysis was conducted for 94 patients diagnosed with a Gleas...

journal_title：Prostate cancer and prostatic diseases

authors： Meziou S,Ringuette Goulet C,Hovington H,Lefebvre V,Lavallée É,Bergeron M,Brisson H,Champagne A,Neveu B,Lacombe D,Beauregard JM,Buteau FA,Riopel J,Pouliot F

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:Certain patients presenting with either low or very-low-risk prostate cancer (PCa) can represent a therapeutic dilemma for physicians. The oncologic outcomes of active surveillance (AS) for men with very-low-risk PCa are overall excellent. However, there are concerns about AS related to the potential for upg...

journal_title：Prostate cancer and prostatic diseases

authors： Gökce MI,Sundi D,Schaeffer E,Pettaway C

更新日期：2017-06-01 00:00:00

abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...

journal_title：Prostate cancer and prostatic diseases

authors： Obek C,Doganca T,Argun OB,Kural AR

更新日期：2020-09-01 00:00:00

abstract：BACKGROUND:To evaluate the safety and clinical feasibility of focal irreversible electroporation (IRE) of the prostate. METHODS:We assessed the toxicity profile and functional outcomes of consecutive patients undergoing focal IRE for localised prostate cancer in two centres. Eligibility was assessed by multi-parametri...

journal_title：Prostate cancer and prostatic diseases

authors： Valerio M,Stricker PD,Ahmed HU,Dickinson L,Ponsky L,Shnier R,Allen C,Emberton M

更新日期：2014-12-01 00:00:00

abstract：:It has been suggested that in multifocal prostate cancer (PCa), focal therapy to the largest (index) lesion is sufficient, because secondary non-index lesions are unlikely to contribute to disease progression. In this study, the role of PCa focality in selecting men for focal therapy was evaluated. A histopathological...

journal_title：Prostate cancer and prostatic diseases

authors： Karavitakis M,Winkler M,Abel P,Livni N,Beckley I,Ahmed HU

更新日期：2011-03-01 00:00:00

abstract：:The role of neoadjuvant androgen deprivation (NAD) in high-risk prostate cancer patients receiving high-dose radiotherapy (RT) remains unstudied. To evaluate the effect of a course of NAD, we reviewed the experiences of three institutions treating these patients with combined RT and high-dose rate brachytherapy (HDR)....

journal_title：Prostate cancer and prostatic diseases

authors： Vargas C,Martínez A,Galalae R,Demanes J,Harsolia A,Schour L,Nuernberg N,Gonzalez J

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Recently, a new prostate cancer (PC) grading system has been introduced, where Gleason score (GS) 7 (3+4) and GS 7 (4+3) are categorized into two separate groups. However, GS 7 with tertiary Gleason pattern 5 (TGP5) was not incorporated in the new grading system. In the present study, we validated the progno...

journal_title：Prostate cancer and prostatic diseases

authors： Jang WS,Yoon CY,Kim MS,Kang DH,Kang YJ,Jeong WS,Abalajon MJ,Ham WS,Choi YD

更新日期：2017-03-01 00:00:00

abstract：BACKGROUND:CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and ge...

journal_title：Prostate cancer and prostatic diseases

authors： Tao L,Chen J,Zhou H,Qin C,Li P,Cao Q,Li J,Ju X,Zhu C,Wang M,Zhang Z,Shao P,Yin C

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common problem with unclear etiology. Some diet and lifestyle factors were thought to correlate with CP/CPPS, but studies comprehensively investigate this correlation are rarely available. The current study was conducted to determine the potenti...

journal_title：Prostate cancer and prostatic diseases

authors： Chen X,Hu C,Peng Y,Lu J,Yang NQ,Chen L,Zhang GQ,Tang LK,Dai JC

更新日期：2016-03-01 00:00:00

abstract：:The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, w...

journal_title：Prostate cancer and prostatic diseases

authors： Stoss O,Werther M,Zielinski D,Middel P,Jost N,Rüschoff J,Henkel T,Albers P

更新日期：2008-01-01 00:00:00

abstract：:Men with diabetes mellitus are less likely to be diagnosed with prostate cancer (PCa). As diabetic men have lower serum PSA, it is unclear if this is due to lower PCa incidence or reflects detection bias from fewer PSA-triggered biopsies. To account for differential biopsy rates, we used multivariate regression to exa...

journal_title：Prostate cancer and prostatic diseases

authors： Wu C,Moreira DM,Gerber L,Rittmaster RS,Andriole GL,Freedland SJ

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Epidemiologic evidence for a serum cholesterol-prostate cancer link is mixed. Prostate-specific antigen (PSA) is positively correlated with cholesterol, potentially increasing PSA-driven biopsy recommendations in men with high cholesterol, though biopsy compliance may be lower in men with comorbid conditions...

journal_title：Prostate cancer and prostatic diseases

authors： Jamnagerwalla J,Howard LE,Allott EH,Vidal AC,Moreira DM,Castro-Santamaria R,Andriole GL,Freeman MR,Freedland SJ

更新日期：2018-06-01 00:00:00

abstract：BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-09-01 00:00:00

abstract：:Increasingly animal and clinical studies suggest that intermittent therapy may improve the duration of hormone dependence in patients with prostate cancer. However there remains uncertainty as to optimal duration of treatment and level of prostate-specific antigen (PSA) before treatment is restarted. The aim of this s...

journal_title：Prostate cancer and prostatic diseases

authors： Oliver RT,Farrugia D,Ansell W,Williams G,Chinegwundoh F

更新日期：2000-12-01 00:00:00

abstract：:To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treat...

journal_title：Prostate cancer and prostatic diseases

authors： Potters L,Fearn P,Kattan M

更新日期：2002-01-01 00:00:00

abstract：:With growing number of older adults in the United States and complexity of issues related to Medicare and other insurances more research is needed to evaluate an effectiveness of the different insurance types in prevention, screening and treatment of cancer. With prostate cancer being highly prevalent disease in older...

journal_title：Prostate cancer and prostatic diseases

authors： Sadetsky N,Elkin EP,Latini DM,DuChane J,Carroll PR,CaPSURE Investigators.

更新日期：2008-01-01 00:00:00

abstract：:Functional expression of voltage-gated sodium channel alpha-subunits (VGSCalphas), specifically Nav1.7, is associated with strong metastatic potential in prostate cancer (CaP) in vitro. Furthermore, VGSC activity in vitro directly potentiates processes integral to metastasis. To investigate VGSCalpha expression in CaP...

journal_title：Prostate cancer and prostatic diseases

authors： Diss JK,Stewart D,Pani F,Foster CS,Walker MM,Patel A,Djamgoz MB

更新日期：2005-01-01 00:00:00

abstract：PURPOSE:To determine whether quantitative flow cytometric androgen receptor density expression (MFC ratio) in prostate cancer was associated with S-phase fraction. METHODS:Flow cytometry was performed to determine DNA aneuploidy, S-phase fraction, percentage of androgen receptor (AR)-positive cells, and MFC ratio in p...

journal_title：Prostate cancer and prostatic diseases

authors： Abdel-Wahab M,Krishan A,Milikowski C,Wahab AA,Walker G,Markoe A

更新日期：2003-01-01 00:00:00